Are myelodysplastic syndromes "cancer"?. Unexpected adverse consequences of linguistic ambiguity

Leukemia Research

Volumn 30, Issue 10, 2006, Pages 1227-1233

  Steensma, David P ^a  

^a MAYO CLINIC   (United States)

Author keywords

Disease classification; Insurance scam; MDS; Neoplasia; Terminology

Indexed keywords

ANDROGEN; ANTHRACYCLINE; AZACITIDINE; CYTARABINE; FLUDARABINE; HEMOPOIETIC GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; LENALIDOMIDE; THYMOCYTE ANTIBODY; TOPOTECAN;

ARTICLE; BLOOD CELL; BONE MARROW CELL; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CANCER RESEARCH; CHROMOSOME ABERRATION; CLINICAL TRIAL; CLONAL VARIATION; CONSENSUS; GENETIC STABILITY; HEALTH CARE ORGANIZATION; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; INCIDENTAL FINDING; INSTITUTIONAL ETHICS; INTENSIVE CARE; MALIGNANT NEOPLASTIC DISEASE; MICROSATELLITE INSTABILITY; MYELOBLAST; MYELODYSPLASTIC SYNDROME; NOMENCLATURE; NON PROFIT ORGANIZATION; PRIORITY JOURNAL; PROGNOSIS; SCIENTIFIC LITERATURE; UNITED STATES; WORLD HEALTH ORGANIZATION;

DISEASE PROGRESSION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LINGUISTICS; MYELODYSPLASTIC SYNDROMES; NEOPLASMS; PROGNOSIS;

EID: 33747140032     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.12.001     Document Type: Article

References (79)

1. Tricot G.J. Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practice. Leuk Res 16 1 (1992) 5-6
2. Ramos F., Fernandez-Ferrero S., Suarez D., et al. Myelodysplastic syndrome: a search for minimal diagnostic criteria. Leuk Res 23 3 (1999) 283-290
3. Head D.R. Proposed changes in the definitions of acute myeloid leukemia and myelodysplastic syndrome: are they helpful?. Curr Opin Oncol 14 1 (2002) 19-23
4. Bennett J.M., Brunning R.D., and Vardiman J.W. Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary. Blood 99 8 (2002) 3074-3075
5. Bennett J.M. A comparative review of classification systems in myelodysplastic syndromes (MDS). Semin Oncol 32 4 Suppl. 5 (2005) S3-S10
6. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 2 (1982) 189-199
7. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 6 (1997) 2079-2088
8. In: Jaffe E.S., Harris N.L., Stein H., et al. (Eds). WHO classification: tumours of haematopoietic and lymphoid tissues (2001), International Agency For Research on Cancer (IARC) Press, Lyon
9. Heaney M.L., and Golde D.W. Myelodysplasia. N Engl J Med 340 21 (1999) 1649-1660
10. Heaney M.L., and Golde D.W. Critical evaluation of the World Health Organization classification of myelodysplasia and acute myeloid leukemia. Curr Oncol Rep 2 2 (2000) 140-143
11. Steensma D.P., and Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res 27 2 (2003) 95-120
12. Greenberg P., Anderson J., de Witte T., et al. Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol 18 19 (2000) 3447-3452
13. Look A.T. Molecular pathogenesis of MDS. Hematol (Am Soc Hematol Educ Program) (2005) 156-160
14. Hofmann W.K., and Koeffler H.P. Myelodysplastic syndrome. Annu Rev Med 56 (2005) 1-16
15. Steensma D.P., and List A.F. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin Proc 80 5 (2005) 681-698
16. Deeg H.J. Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS). Hematol (Am Soc Hematol Educ Program) (2005) 167-173
17. NAIC. National Association of Insurance Commissioners: a shopper's guide to cancer insurance (2004), NAIC Executive Headquarters, Kansas City
18. Anon. Insurance you don't need. Consumer reports (July 2004)
19. Penson R.T., Partridge R.A., Shah M.A., et al. Fear of death. Oncologist 10 2 (2005) 160-169
20. Anon. BBC News UK Scam Watch: 'I'm calling about breast cancer insurance'-presented Wednesday March 10, 2004 (2004), BBC News, London
21. Anon. Frequently asked questions about MDS. Crosswicks, NJ: Myelodysplastic Syndromes Foundation; 2005.
22. Steensma D.P. Reassurance. J Clin Oncol 22 15 (2004) 3196-3198
23. Kumar V., Abbas A.K., and Fausto N. Robbins and Cotran pathologic basis of disease. 7th ed. (2005), Elsevier, Philadelphia
24. Janssen J.W., Buschle M., Layton M., et al. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood 73 1 (1989) 248-254
25. Boultwood J., and Wainscoat J.S. Clonality in the myelodysplastic syndromes. Int J Hematol 73 4 (2001) 411-415
26. Weimar I.S., Bourhis J.H., De Gast G.C., et al. Clonality in myelodysplastic syndromes. Leuk Lymphoma 13 3-4 (1994) 215-221
27. Tsukamoto N., Morita K., Maehara T., et al. Clonality in myelodysplastic syndromes: demonstration of pluripotent stem cell origin using X-linked restriction fragment length polymorphisms. Br J Haematol 83 4 (1993) 589-594
28. van Lom K., Hagemeijer A., Smit E., et al. Cytogenetic clonality analysis in myelodysplastic syndrome: monosomy 7 can be demonstrated in the myeloid and in the lymphoid lineage. Leukemia 9 11 (1995) 1818-1821
29. Abruzzese E., Buss D., Rainer R., et al. Study of clonality in myelodysplastic syndromes: detection of trisomy 8 in bone marrow cell smears by fluorescence in situ hybridization. Leuk Res 20 7 (1996) 551-557
30. Bennett J.M. The clinical implications of the World Health Organization's classification of myelodysplastic syndromes. Curr Hematol Rep 4 3 (2005) 175-181
31. Pedersen-Bjergaard J., Andersen M.K., Christiansen D.H., et al. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 99 6 (2002) 1909-1912
32. Pedersen-Bjergaard J., Pedersen M., Roulston D., et al. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86 9 (1995) 3542-3552
33. Duesberg P., Rausch C., Rasnick D., et al. Genetic instability of cancer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci USA 95 23 (1998) 13692-13697
34. Kaneko H., Horiike S., Taniwaki M., et al. Microsatellite instability is an early genetic event in myelodysplastic syndrome but is infrequent and not associated with TGF-beta receptor type II gene mutation. Leukemia 10 11 (1996) 1696-1699
35. Kita-Sasai Y., Horiike S., Misawa S., et al. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. Br J Haematol 115 2 (2001) 309-312
36. Darley R.L., Hoy T.G., Baines P., et al. Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells. J Exp Med 185 7 (1997) 1337-1347
37. Shih L.Y., Huang C.F., Wang P.N., et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 18 3 (2004) 466-475
38. Padua R.A., Guinn B.A., Al-Sabah A.I., et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 12 6 (1998) 887-892
39. Harada H., Harada Y., Niimi H., et al. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103 6 (2004) 2316-2324
40. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 7 (2002) 2292-2302
41. Albitar M., Manshouri T., Shen Y., et al. Myelodysplastic syndrome is not merely "preleukemia". Blood 100 3 (2002) 791-798
42. Arber D.A., Stein A.S., Carter N.H., et al. Prognostic impact of acute myeloid leukemia classification. Importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival. Am J Clin Pathol 119 5 (2003) 672-680
43. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17 12 (1999) 3835-3849
44. Steliarova-Foucher E., Stiller C., Lacour B., et al. International classification of childhood cancer, third edition. Cancer 103 7 (2005) 1457-1467
45. Fritz A., Percy C., and Jack A. International classification of diseases for oncology (ICD-O-3). 3rd ed. (2000), Geneva: World Health Organization
46. Anon. World Health Organization international statistical classification of diseases and related health problems, 10th revision (ICD-10) (1992), World Health Organization, Geneva
47. List AF, Dewald G, Bennett J., et al. Abstract 5: hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the multicenter MDS-003 study. ASCO annual meeting proceedings. J Clin Oncol 2005;23(165) Part I of II:26.
48. In: Wiernik P., Goldman J.M., Dutcher J.P., et al. (Eds). Neoplastic diseases of the blood (2003), Cambridge University Press, Cambridge
49. In: Kufe D.W., Pollock R.E., Weichselbaum R.R., et al. (Eds). Holland-Frei cancer medicine. 6th ed. (2003), BC Decker, Toronto
50. In: De Vita V.T., De Vita Jr. V.T., Hellman S., et al. (Eds). Cancer: principles and practice of oncology. 7th ed. (2004), Lippincott Williams and Wilkins, Philadelphia
51. Greenberg, P.L., NCCN Panel. National Comprehensive Cancer Network (NCCN) clinical practical guidelines in oncology-v.1.2005: myelodysplastic syndromes (Sep 2004). Chicago, IL: National Comprehensive Cancer Network; 2005.
52. Moreno-Aspitia A., Geyer S., Li C., et al. N998B: multicenter phase II trial of thalidomide (Thal) in adult patients with myelodysplastic syndromes (MDS). Blood 100 (2002) 96a
53. Cherry A.M., Brockman S.R., Paternoster S.F., et al. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Leuk Res 27 12 (2003) 1085-1090
54. Miller K.B., Kim K., Morrison F.S., et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol 65 4 (1992) 162-168
55. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20 10 (2002) 2429-2440
56. List A.F., and Doll D.C. The myelodysplastic syndromes. In: Lee G.R., et al. (Ed). Wintrobe's clinical hematology (1999), Williams & Wilkins, Baltimore 2320-2341
57. di Guglielmo G. Eritremie acute. Boll Soc Med Chir 1 (1926) 665-673
58. Chevallier P. Sur la terminologie des leucoses et les affections-frontieres: les odoleucoses. Sangre (Barc) 15 (1942-1943) 587-593
59. Luzzatto A.M. Sull' anemia grave megaloblastica senza reporto ematologico corrispondente (anemia pseudoaplastica). Riv. veneta di sc. med. Venezia 47 (1907) 193-212
60. Rhoads C.P., and Barker W.H. Refractory anemia: analysis of 100 cases. JAMA 110 (1938) 794-796
61. Hamilton-Paterson J.L. Pre-leukaemic anaemia. Acta Haematol (Basel) 2 (1949) 309-316
62. Block M., Jacobson L.O., and Bethard W.F. Preleukemic acute human leukemia. JAMA 152 (1953) 1018-1028
63. Rheingold J.J., Kaufman R., Adelson E., et al. Smoldering acute leukemia. N Engl J Med 268 (1963) 812-815
64. Oosterveld M., Wittebol S.H., Lemmens W.A., et al. The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups. Br J Haematol 123 1 (2003) 81-89
65. Giralt S. Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions. Curr Hematol Rep 4 3 (2005) 200-207
66. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120 6 (2003) 1037-1046
67. Chan G., DiVenuti G., and Miller K. Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome. Am J Hematol 71 3 (2002) 166-171
68. Molldrem J.J., Leifer E., Bahceci E., et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 137 3 (2002) 156-163
69. Cazzola M., and Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med 352 6 (2005) 536-538
70. Sperr W.R., Wimazal F., Kundi M., et al. Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. Ann Hematol 80 5 (2001) 272-277
71. Piller G. Leukaemia-a brief historical review from ancient times to 1950. Br J Haematol 112 2 (2001) 282-292
72. Bain B.J. Di Guglielmo and his syndromes. Br J Haematol 120 6 (2003) 939-943
73. Degos L. John Hughes Bennett, Rudolph Virchow and Alfred Donne: the first description of leukaemia. Hematol J 2001;2(1):1.
74. Chomsky N. The logical structure of linguistic theory (1975), Plenum, New York
75. Lambert B.L. Predicting look-alike and sound-alike medication errors. Am J Health Syst Pharm 54 10 (1997) 1161-1171
76. Beckman H.B., Markakis K.M., Suchman A.L., et al. The doctor-patient relationship and malpractice. Lessons from plaintiff depositions. Arch Intern Med 154 12 (1994) 1365-1370
77. Gattermann N., Aul C., and Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol 74 1 (1990) 45-52
78. Giagounidis A.A., Germing U., Wainscoat J.S., et al. The 5q-syndrome. Hematology 9 4 (2004) 271-277
79. Helft P.R. Necessary collusion: prognostic communication with advanced cancer patients. J Clin Oncol 23 13 (2005) 3146-3150